Piper Sandler raised the price target for the Karyopharm Therapeutics Inc (NASDAQ:KPTI) stock to “an Overweight”. The rating was released on January 19, 2023, according to finviz. We previously noted in another research note published on November 04, 2022 by RBC Capital Mkts that upgraded the stock from a Sector perform to an Outperform with a price target of $10 for KPTI stock. The research report from JP Morgan has upgraded the stock from Underweight to Neutral, with a price target set at $8. The stock was resumed by Morgan Stanley, who disclosed in a research note on November 19, 2021, to Equal-Weight and set the price objective to $10. In their research brief published August 06, 2021, SVB Leerink analysts downgraded the Karyopharm Therapeutics Inc stock from Outperform to Mkt Perform with a price target of $6.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.36 during the last quarter as opposed to a consensus estimate of -$0.31, which indicates the company missed its estimate by -$0.05, which implies that the company surprised the market by -16.10%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2024) is -$0.33. This is an average of 7 analysts’ earnings, where the high earnings per share estimate is -$0.28 and the low earnings per share estimate is -$0.37. According to 6 analyst estimates, an average revenue estimate of $34.47M is projected for the current quarter with a high revenue estimate of $38.36M and a low estimate of $31.7M.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The latest trade, Performances and Moving Averages give us the following Picture
The firm’s stock price fluctuated -3.82% within the last five trades and 11.03% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 16.15% in the last 6 months and 94.54% was added to its value over the previous 3 months. KPTI stock is trading at a margin of 14.26%, 34.70% and 17.87% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, KPTI deals in the Healthcare domain. The stock is trading -68.99 percent below its 52-week high and 144.57 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -47.76. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Karyopharm Therapeutics Inc’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at -88.71 percent and the profit margin is -97.99 percent, and the company has reported a gross margin of 96.25 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $173.76 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 1.19 that mirrors the cost to be found for sales by the market.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 8.15 percent of Karyopharm Therapeutics Inc shares are owned by insiders, and 66.39 percent are held by financial institutions. Paulson Richard A., the President and CEO at Karyopharm Therapeutics Inc (KPTI) has sold 3,573 shares of firm on Mar 05 ’24 at a price of $1.30 against the total amount of $4645.0. In another inside trade, Paulson Richard A., President and CEO of Karyopharm Therapeutics Inc (NASDAQ:KPTI) sold 19,374 shares of the firm on Mar 01 ’24 for a total worth of $23249.0 at a price of $1.20. An inside trade which took place on Mar 01 ’24, EVP, CFO & Treasurer of Karyopharm Therapeutics Inc Mason Michael sold 6,162 shares of firm against total price of $7394.0 at the cost of $1.20 per share.
